Results 11 to 20 of about 112,622 (301)

99529 The Role of ATF6-Mediated Signaling in PARP Inhibitor Resistant Ovarian Cancer

Journal of Clinical and Translational Science, 2021
IMPACT: This work has the potential to identify targetable pathways conveying resistance to PARP inhibitors that may improve ovarian cancer patient outcomes. OBJECTIVES/GOALS: High grade serous ovarian cancer is the deadliest gynecologic malignancy. PARP
Alexandra, Benjamin Bitler
doaj   +1 more source

PARP Inhibitors in Prostate Cancer [PDF]

Anticancer Research, 2021
Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal, Kayanaat, Grewal, Imad A, Tabbara   +2 more
openaire   +2 more sources

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

npj Precision Oncology, 2022
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients.
Kasia M. Dillon, Raie T. Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltan Szallasi, Atish D. Choudhury, Kent W. Mouw   +7 more
doaj   +1 more source

PARP-1 regulates DNA repair factor availability. [PDF]

, 2018
PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic
Birbe, Ruth, Brand, Lucas J, Cendon-Florez, Ylenia, Chand, Saswati N., de Leeuw, Renée, Dicker, Adam, MD, PhD, Dylgjeri, Emanuela, Evans, Joseph, Feng, Felix Y, Gallagher, Peter, Gaur, Sanchaika, Gomella, Leonard G, Gordon, Nicolas, Han, Sumin, Huang, Fangjin, Kelly, William Kevin, Knudsen, Beatrice, Knudsen, Karen E, Lallas, Costas D, Leiby, Benjamin E, Mandigo, Amy C., McCann, Jennifer J, McCue, Peter, McNair, Christopher, Parsons, Theodore, Poudel Neupane, Neermala, Raj, Ganesh V, Schiewer, M J, Shafi, Ayesha A, Trabulsi, Edouard J, Visakorpi, Tapio, Zhao, Shuang G   +31 more
core   +2 more sources

Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo [PDF]

PeerJ, 2016
Early studies with first-generation poly (ADP-ribose) polymerase (PARP) inhibitors have already indicated some therapeutic potential for sulfur mustard (SM) injuries.
Feng Liu, Ning Jiang, Zhi-yong Xiao, Jun-ping Cheng, Yi-zhou Mei, Pan Zheng, Li Wang, Xiao-rui Zhang, Xin-bo Zhou, Wen-xia Zhou, Yong-xiang Zhang   +10 more
doaj   +2 more sources

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Cell Reports, 2017
Summary: PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors.
Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, Bo Zhao, Nail Fatkhutdinov, Andrew V. Kossenkov, Andrew J. Wilson, Fiona Simpkins, David Speicher, Dineo Khabele, Benjamin G. Bitler, Rugang Zhang   +11 more
doaj   +1 more source

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods [PDF]

PeerJ, 2020
Background Research has shown that Poly-ADP-ribose polymerases 1 (PARP-1) is a potential therapeutic target in the clinical treatment of breast cancer.
Hongye Hu, Buran Chen, Danni Zheng, Guanli Huang   +3 more
doaj   +2 more sources

PARP-3 and APLF function together to accelerate nonhomologous end joining [PDF]

, 2010
PARP-3 is a member of the ADP-ribosyl transferase superfamily of unknown function. We show that PARP-3 is stimulated by DNA double-strand breaks (DSBs) in vitro and functions in the same pathway as the poly (ADP-ribose)-binding protein APLF to accelerate
Ahel, Ame, Anna E.O. Fisher, Audebert, Bekker-Jensen, Benjamin, Bernardo Reina-San-Martin, Boulton, Brown, Bryant, Bryant, Caldecott, Caldecott, Critchlow, Ding, Drouet, El-Khamisy, Farmer, Fisher, Grawunder, Guy Poirier, Hochegger, Hottiger, Iles, Isabelle Robert, Kanno, Keith W. Caldecott, Kickhoefer, Kleine, Le Page, Lehtio, Limei Ju, Lobrich, Loseva, Macrae, Mahaney, Maria C. Zuma, Mehrotra, Michele Rouleau, Morrison, Okano, Otto, Poirier, Robert, Roberts, Rogakou, Rogakou, Rouleau, Rulten, Smith, Soulas-Sprauel, Stevnsner, Stuart L. Rulten, Sugimura, Trucco, Wang, Yan, Yang, Yano, Yano   +59 more
core   +1 more source

Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities

Frontiers in Cellular Neuroscience, 2020
Post-stroke inflammation is almost involved in the whole process of stroke pathogenesis, which serves as a prime target for developing new stroke therapies. Despite known sex differences in the incidence and outcome of stroke, few preclinical or clinical
Jian Chen, Jian Chen, Jian Chen, Xiaoxi Li, Xiaoxi Li, Xiaoxi Li, Siyi Xu, Siyi Xu, Siyi Xu, Meijuan Zhang, Meijuan Zhang, Meijuan Zhang, Zhengzheng Wu, Xi Zhang, Yun Xu, Yun Xu, Yun Xu, Yanting Chen, Yanting Chen, Yanting Chen   +19 more
doaj   +1 more source